Literature DB >> 10458556

ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology.

.   

Abstract

The reduction in the incidence of Rh D alloimmunization is a prototype for the effectiveness of preventive medicine. Some controversies remain, however, such as the use of anti-D immune globulin in patients with either threatened abortion or antenatal hemorrhage. Similarly, it may not be cost-effective either to screen all Rh D-negative patients with an indirect Coombs test at 24-28 weeks of gestation or to screen all postpartum patients for excessive fetomaternal hemorrhage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10458556

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  11 in total

Review 1.  The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation.

Authors:  Giancarlo Maria Liumbruno; Angelo D'Alessandro; Federica Rea; Vanessa Piccinini; Liviana Catalano; Gabriele Calizzani; Simonetta Pupella; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2010-01       Impact factor: 3.443

2.  Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn.

Authors:  Francesco Bennardello; Serelina Coluzzi; Giuseppe Curciarello; Tullia Todros; Stefania Villa
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

3.  Demographics, clinical characteristics and outcomes of neonates diagnosed with fetomaternal haemorrhage.

Authors:  Annemarie Stroustrup; Leonardo Trasande
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-02-28       Impact factor: 5.747

4.  It's time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group.

Authors:  S Gerald Sandler; Willy A Flegel; Connie M Westhoff; Gregory A Denomme; Meghan Delaney; Margaret A Keller; Susan T Johnson; Louis Katz; John T Queenan; Ralph R Vassallo; Clayton D Simon
Journal:  Transfusion       Date:  2014-12-01       Impact factor: 3.157

5.  RHD alleles among pregnant women with serologic discrepant weak D phenotypes from a multiethnic population and risk of alloimmunization.

Authors:  Carolina Bonet Bub; Maria Giselda Aravechia; Thiago Henrique Costa; José Mauro Kutner; Lilian Castilho
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

6.  Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis.

Authors:  Silvia Manfroi; Chiara Calisesi; Pietro Fagiani; Annalisa Gabriele; Gianluca Lodi; Simonetta Nucci; Susanna Pelliconi; Laura Righini; Vanda Randi
Journal:  Blood Transfus       Date:  2018-04-09       Impact factor: 3.443

7.  Rhesus Negative Woman Transfused With Rhesus Positive Blood: Subsequent Normal Pregnancy Without Anti D production.

Authors:  E T Maya; K A Buntugu; F Pobee; E K Srofenyoh
Journal:  Ghana Med J       Date:  2015-03

8.  Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.

Authors:  J M Koelewijn; M de Haas; T G M Vrijkotte; C E van der Schoot; G J Bonsel
Journal:  BJOG       Date:  2009-06-17       Impact factor: 6.531

9.  Successful treatment of fetal intraperitoneal administration of immunoglobulin in a case of fetal hemolytic anemia with 131,072-fold anti-e alloimmunization.

Authors:  Masashi Yoshida; Hideo Matsuda; Eijiro Hayata; Akio Watanabe; Miho Oeda; Kenichi Furuya
Journal:  Case Rep Obstet Gynecol       Date:  2011-11-17

Review 10.  Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review.

Authors:  Trina M Fyfe; M Jane Ritchey; Christorina Taruc; Daniel Crompton; Brian Galliford; Rose Perrin
Journal:  BMC Pregnancy Childbirth       Date:  2014-12-10       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.